Duality is fast-tracking the development of three of its ADC candidates in combination with partner BioNTech's BNT327, an anti-PD-L1/VEGF-A bispecific antibody, in four studies, with certain cohorts evaluating first-line use in various cancers.
FDA approval of Novo Nordisk's Wegovy for MASH was almost as anticipated as approval of the first drug, Madrigal's Rezdiffra. Now, the MASH treatment paradigm should evolve.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alnylam and Roche refine zilebesiran’s Phase III trial design after a Phase II miss, focusing on patients on diuretics.
There is little to divide the Phase III results for the two aldosterone synthase inhibitors, though AstraZeneca’s combination and cardiovascular outcomes studies could bear fruit in the long-term.
MBX Biosciences uses its Precision Endocrine Peptide (PEP) platform to create hormone therapeutics with improved efficacy, durability and tolerability in rare diseases and obesity.
FDA approval of Novo Nordisk's Wegovy for MASH was almost as anticipated as approval of the first drug, Madrigal's Rezdiffra. Now, the MASH treatment paradigm should evolve.
In this week's episode: Lilly’s orforglipron strong in diabetic obesity; Ascletis confident in oral GLP-1 challenger; myostatin drugs progress for obesity; an interview with OneSource’s CEO; and an analysis of Dupixent’s pipeline-in-a-product success.
Plus deals involving Fosun/Accro, Fosun/Sitala, RemeGen/Santen, Firebird/Solasia and more, including tech transfer.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Plus deals involving Fosun/Accro, Fosun/Sitala, RemeGen/Santen, Firebird/Solasia and more, including tech transfer.
Recent moves in the industry include an ex-Pfizer exec as the new CEO at Cha Vaccine Institute and a C-suite shuffle at Paragon Therapeutics, plus six other companies get new CFOs.
Financial announcements that report falling sales or profits may result in share price weakness, while big restructurings, or their extended continuation, can elicit protest votes from shareholders.
